Moleculin Biotech (MBRX) Competitors $1.06 +0.04 (+3.92%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. BDRX, GANX, MDCX, BYSI, KRON, DTIL, IMMX, OKYO, PEPG, and IMRXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Biodexa Pharmaceuticals (BDRX), Gain Therapeutics (GANX), Medicus Pharma (MDCX), BeyondSpring (BYSI), Kronos Bio (KRON), Precision BioSciences (DTIL), Immix Biopharma (IMMX), OKYO Pharma (OKYO), PepGen (PEPG), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Biodexa Pharmaceuticals Gain Therapeutics Medicus Pharma BeyondSpring Kronos Bio Precision BioSciences Immix Biopharma OKYO Pharma PepGen Immuneering Biodexa Pharmaceuticals (NASDAQ:BDRX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of BDRX or MBRX? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in BDRX or MBRX? Moleculin Biotech received 230 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 49.36% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesMoleculin BiotechOutperform Votes23149.36% Underperform Votes23750.64% Does the media favor BDRX or MBRX? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Biodexa Pharmaceuticals and 3 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.96 beat Biodexa Pharmaceuticals' score of 0.57 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodexa Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BDRX or MBRX? Biodexa Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Do analysts prefer BDRX or MBRX? Moleculin Biotech has a consensus price target of $6.00, suggesting a potential upside of 466.04%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BDRX or MBRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Moleculin Biotech N/A -157.44%-97.16% Which has stronger valuation & earnings, BDRX or MBRX? Biodexa Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$83K642.82-$7.66MN/AN/AMoleculin BiotechN/AN/A-$29.77MN/AN/A SummaryBiodexa Pharmaceuticals and Moleculin Biotech tied by winning 7 of the 14 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.84M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E RatioN/A7.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.096.516.774.25Net Income-$29.77M$143.21M$3.22B$248.23M7 Day Performance2.91%3.97%3.26%3.29%1 Month Performance1.92%0.37%0.02%2.42%1 Year Performance-78.88%2.60%18.01%5.54% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.1722 of 5 stars$1.06+3.9%$6.00+466.0%-78.9%$14.84MN/A0.0020Short Interest ↓News CoverageBDRXBiodexa Pharmaceuticals0.4324 of 5 stars$1.51-2.6%N/AN/A$55.18M$83,000.000.0020Short Interest ↑News CoverageGANXGain Therapeutics3.0294 of 5 stars$1.91+0.8%$8.20+329.3%-30.0%$54.91M$50,000.00-1.7420News CoverageMDCXMedicus PharmaN/A$4.09+3.5%$12.00+193.4%N/A$54.87MN/A0.00N/AAnalyst ForecastNews CoverageGap UpHigh Trading VolumeBYSIBeyondSpringN/A$1.57-1.9%N/A-13.4%$54.02M$1.88M0.0080Positive NewsGap UpKRONKronos Bio2.8443 of 5 stars$0.89+4.0%$1.63+83.6%-13.3%$53.96M$9.85M-0.62100Upcoming EarningsPositive NewsDTILPrecision BioSciences4.2753 of 5 stars$5.11-4.1%$37.67+637.1%-45.8%$53.91M$68.70M85.18200Positive NewsIMMXImmix Biopharma3.3034 of 5 stars$1.94+3.7%$7.00+260.8%-2.8%$53.78MN/A-2.289Upcoming EarningsShort Interest ↓News CoverageOKYOOKYO Pharma3.0331 of 5 stars$1.55+2.6%$7.00+351.6%+5.7%$52.45MN/A0.007Short Interest ↓News CoveragePositive NewsPEPGPepGen2.9105 of 5 stars$1.60+4.6%$10.33+545.8%-87.2%$52.31MN/A-0.5430IMRXImmuneering3.7712 of 5 stars$1.45flat$12.50+762.1%-16.2%$52.18M$320,000.00-0.7460Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap Down Related Companies and Tools Related Companies BDRX Competitors GANX Competitors MDCX Competitors BYSI Competitors KRON Competitors DTIL Competitors IMMX Competitors OKYO Competitors PEPG Competitors IMRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts